Table 2 Baseline characteristics and outcomes of patients by GA categories
|  | GA ≤ 15.5% (n = 609) | GA > 15.5% (n = 412) | P value |
|---|---|---|---|
Male, m (%) | 465 (76.4%) | 287 (69.7%) | 0.017 |
Age, y | 58.4 ± 10.0 | 63.0 ± 10.1 | 0.000 |
BMI, kg/m2 | 26.0 ± 3.3 | 25.6 ± 3.1 | 0.126 |
Medical history, n, (%) | |||
 Diabetes mellitus | 73 (12.0%) | 287 (69.7%) | 0.000 |
 Hypertension | 386 (63.4%) | 282 (68.4%) | 0.095 |
 Previous stroke | 62 (10.2%) | 51 (12.4%) | 0.272 |
 Previous myocardial infarction | 40 (6.6%) | 37 (9.0%) | 0.152 |
 Previous CABG | 2 (0.3%) | 6 (1.5%) | 0.067 |
 Previous PCI | 50 (8.2%) | 26 (6.3%) | 0.257 |
Presentations of ACS | Â | Â | 0.319 |
 Unstable angina | 555 (91.1%) | 372 (90.3%) |  |
 Non-STEMI | 23 (3.8%) | 23 (5.6%) |  |
 STEMI | 31 (5.1%) | 17 (4.1%) |  |
Current or previous smoking, n (%) | 339 (55.7%) | 218 (52.9%) | 0.386 |
Baseline laboratory evaluation | |||
 PLT, × 109/L | 220.8 ± 56.6 | 212.0 ± 60.2 | 0.019 |
 TC, mmol/L | 3.9 ± 1.0 | 3.9 ± 0.9 | 0.342 |
 LDL-C, mmol/L | 2.3 ± 0.8 | 2.2 ± 0.7 | 0.356 |
 HDL-C, mmol/L | 1.1 ± 0.2 | 1.1 ± 0.3 | 0.875 |
 TGs, mmol/L | 1.6 ± 0.9 | 1.5 ± 1.0 | 0.451 |
 Creatinine, μmol/L | 71.0 ± 14.4 | 70.7 ± 17.2 | 0.734 |
Glucose indices | |||
 Fasting glucose, mmol/L | 5.4 ± 1.6 | 7.5 ± 2.4 | 0.000 |
 HbA1c, % | 5.9 ± 0.6 | 7.4 ± 1.4 | 0.000 |
 HOMA-IR | 2.1 (1.6–3.1) | 3.3 (1.9–4.9) | 0.000 |
Antiplatelet responsiveness to clopidogrel | |||
 Responders to clopidogrel | 459 (75.4%) | 273 (66.3%) | 0.002 |
 ADPi | 45.4 ± 25.4 | 39.7 ± 23.8 | 0.000 |
 MAADP | 35.2 ± 14.5 | 39.0 ± 13.9 | 0.000 |